Mutant p53R270H gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis

International Journal of Cancer

Volumn 122, Issue 8, 2008, Pages 1701-1709

  Heinlein, Christina ^a   Krepulat, Frauke ^a   Löhler, Jürgen ^a   Speidel, Daniel ^a,b   Deppert, Wolfgang ^a   Tolstonog, Genrich V ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Mammary carcinoma; Mutant p53 gain of function; SV40 early genes; Transgenic mouse model; Tumor progression

Indexed keywords

PROTEIN P53; ARGININE; HISTIDINE; VIRUS T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CARCINOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; GENE MUTATION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; INVASIVE CARCINOMA; LUNG METASTASIS; MISSENSE MUTATION; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CELL TRANSFORMATION; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; LUNG TUMOR; METASTASIS; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; ARGININE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENES, P53; HISTIDINE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MUTATION, MISSENSE; ONCOGENES; PHENOTYPE; POINT MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 40349087171     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23317     Document Type: Article

References (49)

1. Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005;25:6-17.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
3. Deppert W. Mutant p53 Oncogene, vol. 26. Oncogene. Nature publishing group, The Macmillan Building, 4 Crinan Street, London, NI 9XW, UK, 2007.
4. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12:1157-67.
5. Attardi LD, Donehower LA. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res 2005;576:4-21.
6. Blackburn AC, Jerry DJ. Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer? Breast Cancer Res 2002;4:101-11.
7. Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007;26:2177-84.
8. Lozano G. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 2007;17:66-70.
9. Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, Medina D, Naber SP, Jerry DJ. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol 2000;157:2151-9.
10. Andres AC, Schonenberger CA, Groner B, Hennighausen L, LeMeur M, Gerlinger P. Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc Natl Acad Sci USA 1987;84:1299-303.
11. Schulze-Garg C, Lohler J, Gocht A, Deppert W. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 2000;19:1028-37.
12. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature 1992;358:83-6.
13. Krepulat F, Lohler J, Heinlein C, Hermannstadter A, Tolstonog GV, Deppert W. Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice. Oncogene 2005;24:4645-59.
14. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
15. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
16. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000;19:968-88.
17. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D. Regulation of p53 activity through lysine methylation. Nature 2004;432:353-60.
18. Voorhoeve PM, Agami R. Knockdown stands up. Trends Biotechnol 2003;21:2-4.
19. Moreno CS, Ramachandran S, Ashby DG, Laycock N, Plattner CA, Chen W, Hahn WC, Pallas DC. Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56γ knockdown. Cancer Res 2004;64:6978-88.
20. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene 2005;24:7746-55.
21. Ramel S, Sanchez CA, Schimke MK, Neshat K, Cross SM, Raskind WH, Reid BJ. Inactivation of p53 and the development of tetraploidy in the elastase-SV40 T antigen transgenic mouse pancreas. Pancreas 1995;11:213-22.
22. Li R, Sonik A, Stindl R, Rasnick D, Duesberg P. Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. Proc Natl Acad Sci USA 2000;97:3236-41.
23. Murphy KL, Rosen JM. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer. Oncogene 2000;19:1045-51.
24. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 2005;65:8166-73.
25. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83.
26. Wijnhoven SW, Speksnijder EN, Liu X, Zwart E, vanOostrom CT, Beems RB, Hoogervorst EM, Schaap MM, Attardi LD, Jacks T, van Steeg H, Jonkers J, et al. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res 2007;67:4648-56.
27. Bargonetti J, Reynisdottir I, Friedman PN, Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 1992;6:1886-98.
28. Jiang D, Srinivasan A, Lozano G, Robbins PD. SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 1993;8:2805-12.
29. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9.
30. Dobbelstein M, Roth J. The large T antigen of simian virus 40 binds and inactivates p53 but not p73. J Gen Virol 1998;79(Part 12):3079-83.
31. Rushton JJ, Jiang D, Srinivasan A, Pipas JM, Robbins PD. Simian virus 40 T antigen can regulate p53-mediated transcription independent of binding p53. J Virol 1997;71:5620-3.
32. Technau A, Wolff A, Sauder C, Birkner N, Brandner G. p53 in SV40-transformed DNA-damaged human cells binds to its cognate sequence but fails to transactivate target genes. Int J Oncol 2001;18:281-6.
33. Nicholls CD, McLure KG, Shields MA, Lee PW. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem 2002;277:12937-45.
34. Lilyestrom W, Klein MG, Zhang R, Joachimiak A, Chen XS. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev 2006;20:2373-82.
35. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Branson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-60.
36. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72.
37. Deppert W. The yin and yang of p53 in cellular proliferation. Semin Cancer Biol 1994;5:187-202.
38. Levine AJ. The p53 tumor suppressor gene and gene product. Princess Takamatsu Symp 1989;20:221-30.
39. Ahuja D, Saenz-Robles MT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005;24:7729-45.
40. Weiss L. Metastatic inefficiency. Adv Cancer Res 1990;54:159-211.
41. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982;217:998-1003.
42. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG, Rotter V, Blandino G, et al. Mutant p53 enhances nuclear factor KB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 2007;67:2396-401.
43. Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression - potential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007;35:2093-104.
44. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006;25:304-9.
45. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85.
46. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene 2007;26:2202-11.
47. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007;26:2220-5.
48. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007;9:573-80.
49. Ebina M, Martinez A, Birrer MJ, Ilona Linnoila R. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers. Oncogene 2001;20:2579-86.